5,982 Abbott Laboratories $ABT Shares Sold by Wealth Science Advisors LLC

Wealth Science Advisors LLC cut its holdings in shares of Abbott Laboratories (NYSE:ABT) by 71.7% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,363 shares of the healthcare product maker’s stock after selling 5,982 shares during the period. Wealth Science Advisors LLC’s holdings in Abbott Laboratories were worth $234,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in ABT. Copley Financial Group Inc. raised its stake in shares of Abbott Laboratories by 2.1% during the fourth quarter. Copley Financial Group Inc. now owns 4,435 shares of the healthcare product maker’s stock valued at $556,000 after acquiring an additional 93 shares during the last quarter. WealthTrust Axiom LLC grew its stake in shares of Abbott Laboratories by 3.2% in the fourth quarter. WealthTrust Axiom LLC now owns 3,064 shares of the healthcare product maker’s stock worth $384,000 after purchasing an additional 94 shares during the last quarter. St. Johns Investment Management Company LLC increased its holdings in Abbott Laboratories by 1.0% in the second quarter. St. Johns Investment Management Company LLC now owns 9,859 shares of the healthcare product maker’s stock valued at $895,000 after purchasing an additional 101 shares during the period. Davidson Investment Advisors raised its position in Abbott Laboratories by 3.6% during the 2nd quarter. Davidson Investment Advisors now owns 3,084 shares of the healthcare product maker’s stock worth $280,000 after purchasing an additional 106 shares during the last quarter. Finally, Kinloch Capital LLC raised its position in Abbott Laboratories by 0.4% during the 4th quarter. Kinloch Capital LLC now owns 29,202 shares of the healthcare product maker’s stock worth $3,659,000 after purchasing an additional 111 shares during the last quarter. 75.18% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research firms have commented on ABT. Piper Sandler reiterated an “overweight” rating and issued a $118.00 price target (up from $115.00) on shares of Abbott Laboratories in a research report on Friday, July 17th. UBS Group cut their price objective on Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating on the stock in a research note on Tuesday, July 28th. Rothschild & Co Redburn upgraded Abbott Laboratories from a “neutral” rating to a “buy” rating and upped their target price for the company from $119.00 to $127.00 in a report on Friday, October 2nd. Bank of America lowered their price target on shares of Abbott Laboratories from $120.00 to $102.00 in a report on Friday, June 12th. Finally, Robert W. Baird began coverage on shares of Abbott Laboratories in a research report on Wednesday, July 1st. They issued an “outperform” rating and a $121.00 price target on the stock. Three analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $118.88.

Abbott Laboratories Stock Performance

ABT stock opened at $99.71 on Friday. The firm has a market cap of $172.53 billion, a PE ratio of 32.27, a price-to-earnings-growth ratio of 1.83 and a beta of 0.59. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57. The stock has a 50-day moving average price of $106.25 and a 200-day moving average price of $98.35. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $134.50.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, beating the consensus estimate of $1.28 by $0.03. The company had revenue of $12.59 billion for the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%. The firm’s revenue for the quarter was up 13.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, equities research analysts expect that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.5%. Abbott Laboratories’s dividend payout ratio (DPR) is 81.55%.

Abbott Laboratories Profile

Abbott Laboratories (NYSE:ABT) is a diversified healthcare company that develops, manufactures and sells medical devices, diagnostic products, nutritional products and branded generic pharmaceuticals. Founded in 1888 by Wallace C. Abbott, the company serves healthcare providers, institutions, retailers and consumers worldwide.

Abbott’s medical device portfolio includes cardiovascular products, such as coronary stents, structural heart systems and heart failure devices, as well as diabetes-care technologies, including the FreeStyle Libre continuous glucose monitoring system.